Fresenius Medical Care AG (NYSE:FMS - Get Free Report) reached a new 52-week high during mid-day trading on Friday . The company traded as high as $24.35 and last traded at $24.25, with a volume of 248560 shares changing hands. The stock had previously closed at $23.17.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on FMS shares. Truist Financial lifted their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a "hold" rating in a research report on Monday, January 6th. Bank of America upgraded Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research note on Monday, December 2nd. StockNews.com began coverage on Fresenius Medical Care in a report on Friday, January 3rd. They set a "strong-buy" rating on the stock. Finally, Berenberg Bank began coverage on Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a "buy" rating and a $25.60 price objective for the company.
View Our Latest Report on FMS
Fresenius Medical Care Stock Up 1.6 %
The company has a market cap of $14.45 billion, a price-to-earnings ratio of 20.35, a price-to-earnings-growth ratio of 0.75 and a beta of 0.92. The stock's fifty day moving average is $22.87 and its two-hundred day moving average is $21.00. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.
Fresenius Medical Care (NYSE:FMS - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.03. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The company had revenue of $5.23 billion during the quarter, compared to analyst estimates of $5.36 billion. During the same quarter last year, the business posted $0.31 EPS. Sell-side analysts predict that Fresenius Medical Care AG will post 1.53 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Fresenius Medical Care
A number of institutional investors and hedge funds have recently modified their holdings of the company. Moran Wealth Management LLC lifted its position in Fresenius Medical Care by 47.0% in the 3rd quarter. Moran Wealth Management LLC now owns 233,376 shares of the company's stock worth $4,971,000 after buying an additional 74,621 shares during the last quarter. Quantinno Capital Management LP lifted its stake in shares of Fresenius Medical Care by 78.9% in the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company's stock valued at $2,345,000 after acquiring an additional 48,554 shares during the last quarter. Crossmark Global Holdings Inc. boosted its holdings in Fresenius Medical Care by 60.4% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company's stock valued at $1,340,000 after acquiring an additional 23,692 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Fresenius Medical Care during the 3rd quarter valued at about $420,000. Finally, XTX Topco Ltd grew its position in Fresenius Medical Care by 70.8% during the 3rd quarter. XTX Topco Ltd now owns 39,769 shares of the company's stock worth $847,000 after acquiring an additional 16,487 shares during the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.
About Fresenius Medical Care
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
